截止2020年08月10日21時(shí)59分Aptose Biosciences Inc.（APTO）最新價(jià)4.9300，漲跌額-0.0400，漲跌幅0.80%，昨收4.9700，今開(kāi)4.9900，最高4.9900，最低4.8300，成交量194663手。

　　Aptose Biosciences Inc.（APTO）變動(dòng)日期2020年07月20日，變動(dòng)原因增發(fā)，已發(fā)行普通股8676.98萬(wàn)，已發(fā)行優(yōu)先股--，公告日期2020年07月16日，已發(fā)行港股--，已發(fā)行國(guó)內(nèi)股--，已發(fā)行海外股8676.98萬(wàn)，已發(fā)行其他股--。

　　Aptose Biosciences Inc.（APTO）主要指標(biāo)（幣種：美元）：截止2020年03月31日Aptose Biosciences Inc.（APTO）市盈率（TTM）-20.7050169583954，市凈率（MRQ）5.8929681907906，每股收益（TTM）-0.423435495521072，每股凈資產(chǎn)1.14373602262661，每股股息（USD）--，周息率--%，收入總額--，收入總額同比--%，歸母凈利潤(rùn)-1152.60萬(wàn)，歸母凈利潤(rùn)同比-109.335270613876%，毛利率--%，凈利率--%，總股本7627.37萬(wàn)，總市值（USD）5.14億。

　　報(bào)告日期2020年03月31日，年結(jié)日12-31，幣種美元，Aptose Biosciences Inc.（APTO）凈資產(chǎn)收益率-12.72%，總資產(chǎn)凈利率-11.94%。

　　公司介紹： Aptose Biosciences Inc. is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. Aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. In the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies.

　　本站數(shù)據(jù)均為參考數(shù)據(jù)，不具備市場(chǎng)交易依據(jù)。